Rating Change
HC Wainwright & Co. analysts initiated coverage on SOPHiA GENETICS S.A. (NASDAQ:SOPH) with a Buy rating on July 20, 2026.
new coverageNASDAQ:SOPH
HC Wainwright & Co. Initiates Coverage on SOPHiA GENETICS S.A. (SOPH) with Buy
Rating Change HC Wainwright & Co. analysts initiated coverage on SOPHiA GENETICS S.A. (NASDAQ:SOPH) with a Buy rating on July 20, 2026.
Market Context
SOPHiA GENETICS S.A. operates in the Healthcare sector. The stock currently trades at $6.25 with a market capitalization of $321.5M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for SOPHiA GENETICS S.A..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for SOPHiA GENETICS S.A.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 15, 2026 | BTIG | Buy | N/A |
| May 06, 2026 | BTIG | Buy | N/A |
| Apr 15, 2026 | BTIG | Buy | N/A |
| Jan 26, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SOPH Stock Page
Frequently Asked Questions
What does a Buy rating mean for SOPH?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on SOPHiA GENETICS S.A. (NASDAQ:SOPH). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SOPH forecast page.